Dizal Pharmaceutical's Blood Cancer Pipeline Achieves Multiple ASH Annual Meeting Selections

Stock News11-05

Dizal Pharmaceutical Co.,Ltd. (688192.SH) has announced that it will present eight latest clinical research findings from its hematologic oncology pipeline at the 68th American Society of Hematology (ASH) Annual Meeting, scheduled to take place from December 12 to 15 in New Orleans, USA. The presentations will include three oral presentations and five poster displays, covering the company's three core products in the blood cancer field: the highly selective JAK1 inhibitor Gao Ruizhe (golidocitinib), the LYN/BTK dual-target inhibitor birelentinib, and the next-generation EZH1/2 dual-target small molecule inhibitor GW5282.

Among these, Gao Ruizhe and birelentinib have been selected for oral presentations, while clinical research data for GW5282 in relapsed/refractory non-Hodgkin lymphoma (r/r NHL) will also be disclosed for the first time.

Gao Ruizhe is reported to be the world's first and currently only approved highly selective JAK1 inhibitor for peripheral T-cell lymphoma (PTCL). The drug has demonstrated encouraging preliminary efficacy in exploratory studies across multiple T-cell lymphoma subtypes and certain hematologic immune diseases. A total of five latest clinical research updates for Gao Ruizhe have been selected for presentation at this year's meeting.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment